216 related articles for article (PubMed ID: 27758718)
1. Current and Future Drug Treatments for Glioblastomas.
Ohba S; Hirose Y
Curr Med Chem; 2016; 23(38):4309-4316. PubMed ID: 27758718
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Lou E; Peters KB; Sumrall AL; Desjardins A; Reardon DA; Lipp ES; Herndon JE; Coan A; Bailey L; Turner S; Friedman HS; Vredenburgh JJ
Cancer Med; 2013 Apr; 2(2):185-95. PubMed ID: 23634286
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.
Vinjamuri M; Adumala RR; Altaha R; Hobbs GR; Crowell EB
J Neurooncol; 2009 Jan; 91(2):221-5. PubMed ID: 18813874
[TBL] [Abstract][Full Text] [Related]
6. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
[TBL] [Abstract][Full Text] [Related]
7. Management of glioblastoma.
Aoki T; Hashimoto N; Matsutani M
Expert Opin Pharmacother; 2007 Dec; 8(18):3133-46. PubMed ID: 18035958
[TBL] [Abstract][Full Text] [Related]
8. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Raizer JJ; Malkin MG; Kleber M; Abrey LE
Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
[TBL] [Abstract][Full Text] [Related]
10. Future directions in the treatment of malignant gliomas with temozolomide.
Prados MD
Semin Oncol; 2000 Jun; 27(3 Suppl 6):41-6. PubMed ID: 10866349
[TBL] [Abstract][Full Text] [Related]
11. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
12. Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.
Zhang W; Lin Y; Chen B; Song SW; Jiang T
Childs Nerv Syst; 2010 Jan; 26(1):137-43. PubMed ID: 19823845
[TBL] [Abstract][Full Text] [Related]
13. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
14. Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
Kruser TJ; Mehta MP; Kozak KR
J Clin Oncol; 2016 Apr; 34(11):1281-2. PubMed ID: 26884565
[No Abstract] [Full Text] [Related]
15. Reply to T.J. Kruser et al.
Chinot OL; Taphoorn MJ; Bais C; Bourgon R; Phillips HS; Abrey LE; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Cloughesy T
J Clin Oncol; 2016 Apr; 34(11):1282-3. PubMed ID: 26884575
[No Abstract] [Full Text] [Related]
16. [What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Ducray F; Honnorat J
Presse Med; 2007 Sep; 36(9 Pt 2):1249-54. PubMed ID: 17350791
[TBL] [Abstract][Full Text] [Related]
17. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
18. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
19. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Samis Zella MA; Wallocha M; Slotty PJ; Isik G; Hänggi D; Schroeteler J; Ewelt C; Steiger HJ; Sabel M
Acta Neurochir (Wien); 2014 Feb; 156(2):313-23. PubMed ID: 24287680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
